Chronix's Liquid Biopsy Test Shows Promise In Predicting Therapeutic Response To Chemo

Chronix Biomedical's blood-based liquid biopsy test showed promise in predicting therapeutic response to chemotherapy in a blinded proof-of-concept study presented at the American Association for Cancer Research (AACR) annual meeting in New Orleans, Louisiana (April 16-20).

More from Clinical Trials

More from R&D